RESEARCH

SHCC MBCCOP ACCOMPLISHMENTS AND CONTRIBUTIONS

The SHCC Minority-Based Community Clinical Oncology Program, with its novel ancillary programs and dedicated and tireless staff, is an excellent cancer program with national recognition. The program is holistic in approach, and more than 900 patients have participated in NCI-approved clinical oncology trials. Our accomplishments and contributions are partly summarized in the lists below:

PROTOCOL CONCEPT DEVELOPMENT 2011-2012

E1Q11 (formerly E1Q10) update: since our last progress report, we have had four additional reviews by the NCI Division of Cancer Prevention. After extensively revising the study concept per DCP direction, we piloted two study surveys at three institutions. Several changes to the study surveys resulted from the piloting of these tools. The study is now being reviewed by the DCP and we await a response. Data used to support this concept were presented at the 2011 Breast Cancer Symposium in San Francisco, CA.


At the February 2012 SunCoast CCOP Research Base Annual meeting, MBCCOP Principal Investigator Dr. Thomas Lad presented a new cancer control study concept regarding sleep disturbance in cancer patients. This presentation was favorably received by SCUSF and a protocol proposal will be developed.


Dr. Paul Rubinstein, MBCCOP Type A investigator, is the Protocol Chair of A Phase I/II trial of AVD in addition to Brentuximab Vedotin (SGN-35) in Previously Untreated Stage III/IV HIV-Associated Hodgkin Lymphoma study.

OTHER SCIENTIFIC CONTRIBUTIONS 2011-2012

We are currently collaborating with the University of Illinois at Chicago on their P60: Chicago Colon Cancer Patterns of Care Study. The specific aims of this study are:

  1. Conduct a population-based, epidemiologic study of the adequacy of colon cancer care in non-Hispanic Black (AA) and non-Hispanic White (NHW) colon cancer patients;
  2. Identify differences in prior patterns of screening between AA and NHW colon cancer patients;
  3. Identify factors related to delays in diagnosis and treatment in AA and NHW colon cancer patients;
  4. Identify factors related to whether AA and NHW colon cancer patients receive the standard of diagnosis and treatment for colorectal cancer.

After only one month of participation on this trial, we have identified nearly 20 eligible patients are at our institution. We anticipate the referral of approximately 200 patients for trial participation.

We are also awaiting local IRB approval of another UIC collaborative study entitled: Epidemiology of Ovarian Cancer in African American Women (African American Cancer Epidemiology Study [AACES]). The study aims are:

  1. To establish the infrastructure to conduct a case-control study of invasive epithelial ovarian cancer exclusively in African American women;
  2. To determine how risk factors for ovarian cancer in African-American women are similar to or different from established risk factors in women of other races;
  3. To calculate population attributable fractions to determine if differences in the prevalence of risk factors can account for racial differences in ovarian cancer incidence;
  4. To evaluate what factors are predictive of ovarian cancer survival.

We anticipate the referral of 100 patients over a five year period.

In addition to the above mentioned local trial participation, our investigators have published ten abstracts, one specifically analyzing MBCCOP accrual activity; an article in SSO’s Annuals of Surgical Oncology regarding p53 in women with breast cancer; and presented one poster on Disparities in Head and Neck Cancer: Assessing Delay in Treatment Initiation, a second on Reproductive Health and Endocrine Disruption in Breast Cancer Care, a third in Cervical Dysplasia and Cancer in Women 35 Years of Age and Older and lastly, a presentation on Stage Distribution of Gynecologic Cancers at a Tertiary Care County Hospital.